Does multidetector CT attenuation change in colon cancer liver metastases treated with90Y help predict metabolic activity at FDG PET?

Radiology

Volumn 255, Issue 1, 2010, Pages 164-172

  Tochetto, Sandra M ^a   Rezai, Pedram ^a   Rezvani, Maryam ^a   Nikolaidis, Paul ^a   Berggruen, Senta ^a   Atassi, Bassel ^a   Salem, Riad ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOHEXOL; MICROSPHERE; YTTRIUM 90;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SIZE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LIVER METASTASIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IOHEXOL; MALE; MICROSPHERES; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 77950373217     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09091028     Document Type: Article

References (38)

1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
2. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
3. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(suppl 2):4-7.
4. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759.
5. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008;28(1):81-99.
6. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354(5):496-507.
7. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29(6):815-820.
8. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20(22):4453-4458.
9. Arulampalam TH, Costa DC, Loizidou M, Visvikis D, Ell PJ, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg 2001;88(2):176-189.
10. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41(7):1177-1189.
11. Funaioli C, Pinto C, Di Fabio F, et al. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori 2007;93(6):611-615.
12. de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19(2):348-352.
13. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases . Cancer 2005;104(12):2658-2670.
14. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres - safety, efficacy, and survival. Radiology 2008;247(2):507-515.
15. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. I. Technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8):1251-1278.
16. Keil S, Behrendt FF, Stanzel S, et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices - comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008;18(11):2456-2465.
17. Moltz JH, Bornemann L, Kuhnigk JM, et al. Advanced segmentation techniques for lung nodules, liver metastases, and enlarged lymph nodes in CT scans. IEEE J Sel Top Signal Proc 2009;3(1):122-134.
18. Bornemann L, Dicken V, Kuhnigk JM, Wormanns D, Shin HO. OncoTREAT: a software assistant for cancer therapy monitoring. Int J Comput Assist Radiol Surg 2007;1(5):231-242.
19. Kuhnigk JM, Dicken V, Bornemann L, et al. Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. IEEE Trans Med Imaging 2006;25(4):417-434.
20. Soyer P, Poccard M, Boudiaf M, et al. Detection of hypovascular hepatic metasta ses at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic fi ndings. Radiology 2004;231(2):413-420.
21. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49(4):1185-1193.
22. Vriens D, de Geus-Oei LF, van Laarhoven HW, et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nucl Med Commun 2009;30(7):550-557.
23. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004;31(11):1471-1478.
24. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47(6):1059-1066.
25. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773-1782.
26. Hopper KD, Kasales CJ, Eggli KD, et al. The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr 1996;20(6):930-937.
27. Dachman AH, MacEneaney PM, Adedipe A, Carlin M, Schumm LP. Tumor size on computed tomography scans: is one measurement enough? Cancer 2001;91(3):555-560.
28. Tran LN, Brown MS, Goldin JG, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 2004;11(12):1355-1360.
29. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 2002;225(2):416-419.
30. Gönen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology 2001;221(3):763-767.
31. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
32. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30(5):969-977.
33. Denecke T, Rühl R, Hildebrandt B, et al . Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques . Eur Radiol 2008;18(5):892-902.
34. Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radio-Graphics 2008;28(1):101-117.
35. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248(3):894-900.
36. Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007;188(3):776-783.
37. Orlacchio A, Schillaci O, Fusco N, et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009 May 14.
38. Wiering B, Vogel WV, Ruers TJ, Oyen WJ. Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 2008;25(6):413-420.